{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T18:41:09Z","timestamp":1713811269963},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2012,4,5]],"date-time":"2012-04-05T00:00:00Z","timestamp":1333584000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Infect Dis Rep"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1007\/s11908-012-0256-6","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T00:10:13Z","timestamp":1333498213000},"page":"246-255","source":"Crossref","is-referenced-by-count":12,"title":["Mapping the Risk of Yellow Fever Infection"],"prefix":"10.1007","volume":"14","author":[{"given":"David R.","family":"Hill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,4,5]]},"reference":[{"key":"256_CR1","unstructured":"\u2022 Informal Working Group on Geographic Risk of Yellow Fever, World Health Organization. Background for the consultation on yellow fever and international travel, 2010 (update February 2011). 2011, World Health Organization: Geneva. p. 1\u201347. Available at: http:\/\/www.who.int\/ith\/YFrisk.pdf . Provides all of the background information and rationale for YF risk categorisation."},{"key":"256_CR2","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/S1473-3099(11)70147-5","volume":"11","author":"ES Jentes","year":"2011","unstructured":"\u2022\u2022 Jentes ES, Poumerol G, Gershman MD, et al. The revised global yellow fever risk map and recommendations for vaccination, 2010: consensus of the Informal WHO Working Group on Geographic Risk for Yellow Fever. Lancet Infect Dis. 2011;11:622\u201332. Definitive paper describing the process and outcomes of the YF risk mapping.","journal-title":"Lancet Infect Dis"},{"key":"256_CR3","first-page":"401","volume":"86","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Revised recommendations for yellow fever vaccination for international travellers, 2011. Wkly Epidemiol Rec. 2011;86:401\u201311.","journal-title":"Wkly Epidemiol Rec"},{"key":"256_CR4","volume-title":"International travel and health","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. International travel and health. Geneva: World Health Organization; 2011."},{"key":"256_CR5","volume-title":"CDC health information for international travel 2012","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. CDC health information for international travel 2012. Atlanta: US Department of Health and Human Services, Public Health Service; 2011."},{"key":"256_CR6","first-page":"465","volume":"85","author":"World Health Organization","year":"2010","unstructured":"\u2022 World Health Organization. Yellow fever surveillance and outbreak response: revision of case definitions, October 2010. Wkly Epidemiol Rec. 2010;85:465\u201372. Review and publication of new case definitions for YF surveillance.","journal-title":"Wkly Epidemiol Rec"},{"key":"256_CR7","first-page":"370","volume":"86","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Yellow fever in the WHO African and American Regions, 2010. Wkly Epidemiol Rec. 2011;86:370\u20136.","journal-title":"Wkly Epidemiol Rec"},{"key":"256_CR8","first-page":"1","volume-title":"2005","author":"World Health Organization. International Health Regulations","year":"2005","unstructured":"World Health Organization. International Health Regulations (2005) Geneva: World Health Organization; 2005. p. 1\u201360."},{"key":"256_CR9","first-page":"895","volume":"59","author":"JD Poland","year":"1981","unstructured":"Poland JD, Calisher CH, Monath TP, et al. Persistence of neutralizing antibody 30\u201335\u00a0years after immunization with 17D yellow fever vaccine. Bull World Health Organ. 1981;59:895\u2013900.","journal-title":"Bull World Health Organ"},{"key":"256_CR10","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s13149-011-0135-7","volume":"104","author":"H Coulange Bodilis","year":"2011","unstructured":"Coulange Bodilis H, Benabdelmoumen G, Gergely A, et al. Long term persistence of yellow fever neutralising antibodies in elderly persons. Bull Soc Pathol Exot. 2011;104:260\u20135.","journal-title":"Bull Soc Pathol Exot"},{"key":"256_CR11","unstructured":"Sawyer WA. The present geographic distribution of yellow fever and its significance. In: The Harvey lectures. New York: The Williams & Wilkins Company; 1936. p. 66\u201392."},{"key":"256_CR12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1126\/science.71.1840.367","volume":"71","author":"M Theiler","year":"1930","unstructured":"Theiler M. Susceptibility of white mice to the virus of yellow fever. Science. 1930;71:367.","journal-title":"Science"},{"key":"256_CR13","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1084\/jem.54.4.533","volume":"54","author":"WA Sawyer","year":"1931","unstructured":"Sawyer WA, Lloyd W. The use of mice in tests of immunity against yellow fever. J Exp Med. 1931;54:533\u201355.","journal-title":"J Exp Med"},{"key":"256_CR14","volume-title":"Virus diseases of man","author":"C Rooyan Van","year":"1948","unstructured":"Van Rooyan C, Rhodes A. Virus diseases of man. 2nd ed. New York: Nelson; 1948.","edition":"2"},{"key":"256_CR15","first-page":"687","volume":"1","author":"United Nations Relief and Rehabilitation Administration","year":"1945","unstructured":"United Nations Relief and Rehabilitation Administration. Third report of the expert commission on quarantine. Epidemiol Inf Bull. 1945;1:687\u2013701.","journal-title":"Epidemiol Inf Bull"},{"key":"256_CR16","first-page":"539","volume-title":"Yellow fever","author":"HH Smith","year":"1951","unstructured":"Smith HH. Controlling yellow fever. In: Strode GK, editor. Yellow fever. New York: McGraw-Hill Book Co; 1951. p. 539\u2013628."},{"key":"256_CR17","first-page":"325","volume":"11","author":"PH Bonnel","year":"1954","unstructured":"Bonnel PH, Deutschman Z. La fi\u00e8vre jaune en Afrique au cours des ann\u00e9es r\u00e9centes. Bull WHO. 1954;11:325\u201389.","journal-title":"Bull WHO"},{"key":"256_CR18","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","volume":"26","author":"NP Lindsey","year":"2008","unstructured":"Lindsey NP, Schroeder BA, Miller ER, et al. Adverse event reports following yellow fever vaccination. Vaccine. 2008;26:6077\u201382.","journal-title":"Vaccine"},{"key":"256_CR19","first-page":"105","volume":"83","author":"World Health Organization","year":"2008","unstructured":"World Health Organization. Outbreak news. Yellow fever, Paraguay. Wkly Epidemiol Rec. 2008;83:105.","journal-title":"Wkly Epidemiol Rec"},{"key":"256_CR20","first-page":"25","volume":"86","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Yellow fever in Africa and Central and South America, 2008\u20132009. Wkly Epidemiol Rec. 2011;86:25\u201336.","journal-title":"Wkly Epidemiol Rec"},{"key":"256_CR21","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ajp.20796","volume":"72","author":"I Holzmann","year":"2010","unstructured":"Holzmann I, Agostini I, Areta JI, et al. Impact of yellow fever outbreaks on two howler monkey species (Alouatta guariba clamitans and A. caraya) in Misiones, Argentina. Am J Primatol. 2010;72:475\u201380.","journal-title":"Am J Primatol"},{"key":"256_CR22","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1590\/S0034-89102010005000046","volume":"44","author":"PF Vasconcelos","year":"2010","unstructured":"\u2022 Vasconcelos PF. Yellow fever in Brazil: thoughts and hypotheses on the emergence in previously free areas. Rev Sa\u00fade P\u00fablica. 2010;44:1144\u20139. Thoughtful consideration of risk factors for reemergence of YF in S\u00e3o Paolo State in Brazil.","journal-title":"Rev Sa\u00fade P\u00fablica"},{"key":"256_CR23","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1590\/S0037-86822011005000041","volume":"44","author":"ES Moreno","year":"2011","unstructured":"Moreno ES, Rocco IM, Bergo ES, et al. Reemergence of yellow fever: detection of transmission in the State of S\u00e3o Paulo, Brazil, 2008. Rev Soc Bras Med Trop. 2011;44:290\u20136.","journal-title":"Rev Soc Bras Med Trop"},{"key":"256_CR24","doi-asserted-by":"crossref","first-page":"e483","DOI":"10.1371\/journal.pntd.0000483","volume":"3","author":"S Briand","year":"2009","unstructured":"Briand S, Beresniak A, Nguyen T, et al. Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach. PLoS Negl Trop Dis. 2009;3:e483.","journal-title":"PLoS Negl Trop Dis"},{"key":"256_CR25","first-page":"427","volume-title":"Yellow fever","author":"RM Taylor","year":"1951","unstructured":"Taylor RM. Epidemiology. In: Strode GK, editor. Yellow fever. New York: McGraw-Hill Book Co; 1951. p. 427\u2013538."},{"key":"256_CR26","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1590\/S0037-86822011005000024","volume":"44","author":"FP Camara","year":"2011","unstructured":"\u2022 Camara FP, Gomes AL, Carvalho LM, Castello LG. Dynamic behavior of sylvatic yellow fever in Brazil (1954\u20132008). Rev Soc Bras Med Trop. 2011;44:297\u20139. Investigates the occurrence of YF epidemics in Brazil over several decades and determines that there is a 7\u00a0year cycle in central-western regions and a 14\u00a0year cycle in the northern region.","journal-title":"Rev Soc Bras Med Trop"},{"key":"256_CR27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","volume":"358","author":"PF Vasconcelos","year":"2001","unstructured":"Vasconcelos PF, Luna EJ, Galler R, et al. Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet. 2001;358:91\u20137.","journal-title":"Lancet"},{"key":"256_CR28","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","volume":"358","author":"M Martin","year":"2001","unstructured":"Martin M, Tsai TF, Cropp B, et al. Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases. Lancet. 2001;358:98\u2013104.","journal-title":"Lancet"},{"key":"256_CR29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","volume":"358","author":"RC Chan","year":"2001","unstructured":"Chan RC, Penney DJ, Little D, et al. Hepatitis and death following vaccination with 17D-204 yellow fever vaccine. Lancet. 2001;358:121\u20132.","journal-title":"Lancet"},{"key":"256_CR30","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(01)06914-8","volume":"358","author":"V Adhiyaman","year":"2001","unstructured":"Adhiyaman V, Oke A, Cefai C. Effects of yellow fever vaccination. Lancet. 2001;358:1907\u20138.","journal-title":"Lancet"},{"key":"256_CR31","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/S0140-6736(01)06916-1","volume":"358","author":"N Troillet","year":"2001","unstructured":"Troillet N, Laurencet F. Effects of yellow fever vaccination. Lancet. 2001;358:1908\u20139.","journal-title":"Lancet"},{"key":"256_CR32","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(01)06917-3","volume":"358","author":"U Werfel","year":"2001","unstructured":"Werfel U, Popp W. Effects of yellow fever vaccination. Lancet. 2001;358:1909.","journal-title":"Lancet"},{"key":"256_CR33","first-page":"643","volume":"50","author":"Centers for Disease Control and Prevention","year":"2001","unstructured":"Centers for Disease Control and Prevention. Fever, jaundice, and multiple organ system failure associated with 17D-derived yellow fever vaccination, 1996\u20132001. MMWR. 2001;50:643\u20135.","journal-title":"MMWR"},{"key":"256_CR34","first-page":"1","volume":"59","author":"JE Staples","year":"2010","unstructured":"\u2022\u2022 Staples JE, Gershman M, Fischer M. Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010;59:1\u201327. Key resource that reviews all aspects of YF vaccination.","journal-title":"MMWR Recomm Rep"},{"key":"256_CR35","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1016\/j.vaccine.2011.04.055","volume":"29","author":"RE Thomas","year":"2011","unstructured":"\u2022\u2022 Thomas RE, Lorenzetti DL, Spragins W, et al. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review. Vaccine. 2011;29:4544\u201355. Comprehensive review of the literature for SAE associated with YF vaccination.","journal-title":"Vaccine"},{"key":"256_CR36","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","volume":"86","author":"RE Thomas","year":"2012","unstructured":"\u2022 Thomas RE, Lorenzetti DL, Spragins W, et al. The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV + individuals, and older persons: systematic review. Am J Trop Med Hyg. 2012;86:359\u201372. Sub-analysis of SAE in persons with special health needs who have received YF vaccination.","journal-title":"Am J Trop Med Hyg"},{"key":"256_CR37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/157488611797579258","volume":"6","author":"RE Thomas","year":"2011","unstructured":"Thomas RE, Lorenzetti DL, Spragins W, et al. Reporting rates of yellow fever vaccine 17D or 17DD-associated serious adverse events in pharmacovigilance data bases: systematic review. Curr Drug Saf. 2011;6:145\u201354.","journal-title":"Curr Drug Saf"},{"key":"256_CR38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-3156.1998.00164.x","volume":"3","author":"SD Nishioka","year":"1998","unstructured":"Nishioka SD, Nunes-Araujo FRF, Pires WP, et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health. 1998;3:29\u201333.","journal-title":"Trop Med Int Health"},{"key":"256_CR39","first-page":"131","volume":"85","author":"K Kengsakul","year":"2002","unstructured":"Kengsakul K, Sathirapongsasuti K, Punyagupta S. Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection. J Med Assoc Thai. 2002;85:131\u20134.","journal-title":"J Med Assoc Thai"},{"key":"256_CR40","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1590\/S0037-86822009000100006","volume":"42","author":"LM Mota","year":"2009","unstructured":"Mota LM, Oliveira AC, Lima RA, et al. Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases. Rev Soc Bras Med Trop. 2009;42:23\u20137.","journal-title":"Rev Soc Bras Med Trop"},{"key":"256_CR41","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.3201\/eid1710.101789","volume":"17","author":"SJ Seligman","year":"2011","unstructured":"\u2022 Seligman SJ. Yellow fever virus vaccine-associated deaths in young women. Emerg Infect Dis. 2011;17:1891\u20133. Analysis of nine cases of fatal YELAVD, all of which occurred in women aged 19\u201334\u00a0years.","journal-title":"Emerg Infect Dis"},{"key":"256_CR42","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0140-6736(04)17017-7","volume":"364","author":"R Barwick Eidex","year":"2004","unstructured":"Barwick Eidex R, for the Yellow Fever Vaccine Safety Working Group. History of thymoma and yellow fever vaccination (letter). Lancet. 2004;364:936.","journal-title":"Lancet"},{"key":"256_CR43","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.trstmh.2007.06.013","volume":"101","author":"EB Hayes","year":"2007","unstructured":"Hayes EB. Acute viscerotropic disease following vaccination against yellow fever. Trans Roy Soc Trop Med Hyg. 2007;101:967\u201371.","journal-title":"Trans Roy Soc Trop Med Hyg"},{"key":"256_CR44","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","volume":"197","author":"HG Bae","year":"2008","unstructured":"Bae HG, Domingo C, Tenorio A, et al. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe. J Infect Dis. 2008;197:1577\u201384.","journal-title":"J Infect Dis"},{"key":"256_CR45","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1086\/590187","volume":"198","author":"B Pulendran","year":"2008","unstructured":"Pulendran B, Miller J, Querec TD, et al. Case of yellow fever vaccine\u2013associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis. 2008;198:500\u20137.","journal-title":"J Infect Dis"},{"key":"256_CR46","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.coi.2009.05.018","volume":"21","author":"AD Barrett","year":"2009","unstructured":"\u2022 Barrett AD, Teuwen DE. Yellow fever vaccine\u2013how does it work and why do rare cases of serious adverse events take place? Curr Opin Immunol. 2009;21:308\u201313. Review of the possible pathogenic mechanisms for SAE in YF vaccine recipients.","journal-title":"Curr Opin Immunol"},{"key":"256_CR47","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1128\/CVI.00369-09","volume":"17","author":"ML Silva","year":"2010","unstructured":"Silva ML, Espirito-Santo LR, Martins MA, et al. Clinical and immunological insights on severe, adverse neurotropic and viscerotropic disease following 17D yellow fever vaccination. Clin Vaccine Immunol. 2010;17:118\u201326.","journal-title":"Clin Vaccine Immunol"},{"key":"256_CR48","doi-asserted-by":"crossref","first-page":"e27753","DOI":"10.1371\/journal.pone.0027753","volume":"6","author":"AH Roukens","year":"2011","unstructured":"\u2022 Roukens AH, Soonawala D, Joosten SA, et al. Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: a prospective controlled cohort study. PLoS ONE. 2011;6:e27753. Demonstration of how persons aged \u226560\u00a0years handle YF vaccine virus, compared with a younger cohort.","journal-title":"PLoS One"},{"key":"256_CR49","first-page":"130","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","unstructured":"Centers for Disease Control and Prevention. Transmission of yellow fever vaccine virus through breast-feeding\u2013Brazil, 2009. MMWR Morb Mortal Wkly Rep. 2010;59:130\u20132.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"256_CR50","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1708-8305.2010.00430.x","volume":"17","author":"LH Chen","year":"2010","unstructured":"Traiber C, Coelho-Amaral P, Ritter VR, Winge A. Infant meningoencephalitis caused by yellow fever vaccine virus transmitted by breast milk. J Pediatr (Rio J). 2011;87:269\u201372.","journal-title":"J Trav Med"},{"key":"256_CR51","doi-asserted-by":"crossref","first-page":"E243","DOI":"10.1503\/cmaj.100619","volume":"183","author":"S Kuhn","year":"2011","unstructured":"\u2022 Kuhn S, Twele-Montecinos L, MacDonald J, et al. Case report: probable transmission of vaccine strain of yellow fever virus to an infant via breast milk. CMAJ. 2011;183:E243\u20135. One of three cases of YF vaccine virus transmission to infants who are breast-feeding.","journal-title":"CMAJ"},{"key":"256_CR52","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1056\/NEJMoa1009303","volume":"364","author":"TP Monath","year":"2011","unstructured":"\u2022 Monath TP, Fowler E, Johnson CT, et al. An inactivated cell-culture vaccine against yellow fever. N Engl J Med. 2011;364:1326\u201333. Trial of an inactivated YF vaccine demonstrating good immunogenicty and tolerabilty.","journal-title":"N Engl J Med"},{"key":"256_CR53","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","volume":"25","author":"AW McMahon","year":"2007","unstructured":"McMahon AW, Eidex RB, Marfin AA, et al. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases. Vaccine. 2007;25:1727\u201334.","journal-title":"Vaccine"}],"container-title":["Current Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0256-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11908-012-0256-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11908-012-0256-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T18:24:04Z","timestamp":1713810244000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11908-012-0256-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,5]]},"references-count":53,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["256"],"URL":"https:\/\/doi.org\/10.1007\/s11908-012-0256-6","relation":{},"ISSN":["1523-3847","1534-3146"],"issn-type":[{"value":"1523-3847","type":"print"},{"value":"1534-3146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,5]]}}}